Related Experiment Video

Updated: Jun 13, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Prevention of stroke in patients with high-risk atrial fibrillation

Richard A Bernstein1, Rod Passman

  • 1Davee Department of Neurology, Stroke Program, Feinberg School of Medicine of Northwestern University, 710 North Lake Shore Drive, Abbott Hall, 11th Floor, Chicago, IL, 60611, USA. r-bernstein@northwestern.edu

Current Neurology and Neuroscience Reports
|April 29, 2010
PubMed

Insights

Atrial fibrillation (AF) stroke prevention is crucial. This review guides current and emerging treatments and diagnostics for AF patients, offering alternatives to warfarin and improving stroke risk detection.

Area of Science:

  • Cardiology
  • Neurology
  • Internal Medicine

Background:

  • Atrial fibrillation (AF) is a significant cause of ischemic stroke, accounting for nearly 10% of all cases.
  • Warfarin is the standard long-term oral anticoagulation for stroke prevention in AF, but it is underutilized and unsuitable for some patients.
  • Emerging alternatives and diagnostic advancements are crucial for optimizing stroke prevention in AF.

Purpose of the Study:

  • To provide a practical guide to current and emerging stroke prevention strategies for patients with atrial fibrillation.
  • To review new diagnostic modalities for detecting paroxysmal AF.
  • To discuss nonpharmacologic approaches to stroke prevention in AF.

Main Methods:

  • Review of recent clinical trials on AF stroke prevention.
  • Analysis of current treatment options, including warfarin alternatives.
  • Evaluation of new diagnostic technologies for AF detection.

Main Results:

  • Several alternatives to long-term warfarin therapy are being tested and have emerged.
  • Nonpharmacologic stroke prevention strategies for AF are under development.
  • New diagnostic tools offer increased sensitivity for detecting paroxysmal AF.

Conclusions:

  • Optimizing stroke prevention in AF requires considering alternatives to warfarin and utilizing advanced diagnostics.
  • Expanding the population eligible for treatment through improved detection can enhance the impact of preventive strategies.
  • This review offers a practical framework for clinicians managing stroke risk in AF patients.

More Related Videos

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology10:46

Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology

Published on: May 26, 2015

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Atherosclerosis IV: Nursing Management01:23

Atherosclerosis IV: Nursing Management

Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...